Council for International Organizations of Medical Sciences (CIOMS) VIII Working Group on Safety Signal Detection.
ERIC BLOMME, DVM, PHD, is currently leader of the cellular and molecular toxicology group at Abbott Laboratories.
EUGENE C. BUTCHER, MD, is a professor in the Department of Pathology at Stanford University and a staff physician in the Veterans Affairs Palo Alto Health Care System. He received a BS in chemistry from the Massachusetts Institute of Technology and an MD from the Washington University School of Medicine, St. Louis, Missouri. His work has focused on the cellular and molecular mechanisms of leukocyte trafficking in immunity and inflammation, and on systems-level insights into mechanisms of cell–cell recognition and function. He has been elected to the Association of American Physicians and has been awarded the Warner Lambert/Parke Davis Award by the American Association of Pathologists, the AAI-Huang Foundation Meritorious Career Award by the American Association of Immunologists, and an Outstanding Inventor Award from Stanford University. He received the Crafoord Prize from the Swedish Academy of Sciences in 2004 for the scientific discovery of mechanisms of leukocyte trafficking contributing to the treatment of arthritis and inflammatory diseases. Dr. Butcher has been active in biotechnology, most recently cofounding and serving as chair of the Scientific Advisory Board of Bioseek, Inc. He previously helped found Leukosite, Inc., and has served on the scientific advisory boards of Millennium, Medimmune, and Thios Pharmaceuticals.
MARK I. COCKETT, PHD, joined Bristol-Myers Squibb (BMS) in January 2000, and is responsible for functional genomics and bioinformatics applied to preclinical research and development. His group manages and supports key strategic alliances with Lexicon, Artemis, Xenogen, Athersys, Pharmagene/Asterand, Exelixis, Iconix, and the Broad Institute, and is a centralized resource supporting all therapeutic areas at BMS. Before joining BMS, Dr. Cockett worked for 7 years in the neuroscience group at Wyeth, ultimately as Director, Molecular and Cell Biology, and for 10 years in the biotechnology industry for Celltech PLC, where he worked on mammalian gene expression technology and in oncology. While at Celltech, he obtained his PhD in collaboration with the Strange-way Research Laboratory, Cambridge, United Kingdom, working on the involvement of matrix metalloproteinases in tumor cell invasion. Dr. Cockett has published more than 40 peer-reviewed articles in the fields of recombinant gene expression in mammalian cells; the biochemistry and function of several matrix metalloproteinase enzymes and their role